 Structure-Activity Relationship
"Structure-Activity Relationship" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
| Descriptor ID |
D013329
|
| MeSH Number(s) |
G02.111.830 G07.690.773.997
|
| Concept/Terms |
Structure-Activity Relationship- Structure-Activity Relationship
- Relationship, Structure-Activity
- Relationships, Structure-Activity
- Structure Activity Relationship
- Structure-Activity Relationships
|
Below are MeSH descriptors whose meaning is more general than "Structure-Activity Relationship".
Below are MeSH descriptors whose meaning is more specific than "Structure-Activity Relationship".
This graph shows the total number of publications written about "Structure-Activity Relationship" by people in this website by year, and whether "Structure-Activity Relationship" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 7 | 7 | | 1996 | 0 | 12 | 12 | | 1997 | 0 | 7 | 7 | | 1998 | 0 | 7 | 7 | | 1999 | 0 | 9 | 9 | | 2000 | 0 | 13 | 13 | | 2001 | 0 | 8 | 8 | | 2002 | 0 | 20 | 20 | | 2003 | 0 | 12 | 12 | | 2004 | 0 | 12 | 12 | | 2005 | 0 | 12 | 12 | | 2006 | 0 | 17 | 17 | | 2007 | 0 | 21 | 21 | | 2008 | 0 | 10 | 10 | | 2009 | 0 | 14 | 14 | | 2010 | 0 | 11 | 11 | | 2011 | 0 | 19 | 19 | | 2012 | 0 | 18 | 18 | | 2013 | 0 | 12 | 12 | | 2014 | 0 | 10 | 10 | | 2015 | 0 | 16 | 16 | | 2016 | 1 | 17 | 18 | | 2017 | 1 | 20 | 21 | | 2018 | 0 | 20 | 20 | | 2019 | 0 | 18 | 18 | | 2020 | 1 | 12 | 13 | | 2021 | 0 | 14 | 14 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 5 | 5 | | 2025 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Structure-Activity Relationship" by people in Profiles.
-
Thirman HL, Grider-Hayes MJ, Geben LC, Ihrie RA, Brown LE, Porco JA, Irish JM. Connecting chemical structure to single cell signaling profiles. Commun Biol. 2025 Jul 31; 8(1):1137.
-
Muthu Ramalingam B, Sears JD, Talbot KM, Su YN, Houliston S, Hossain MA, Davis-Gilbert ZW, Zhao C, Oh HJ, Brown PJ, Sanders MK, Moorman SR, Ojha D, Burdick JE, Law I, Morales NL, Martinez SA, Loppnau P, Garcia Perez J, Drobish AM, Morrison TE, Streblow ZJ, Streblow DN, Arrowsmith CH, Vargason A, Couñago RM, Halabelian L, Arnold JJ, Cameron CE, Moorman NJ, Heise MT, Willson TM. Identification of Direct-Acting nsP2 Helicase Inhibitors with Antialphaviral Activity. J Med Chem. 2025 Jul 24; 68(14):14514-14536.
-
Vann KR, Sharma R, Hsu CC, Devoucoux M, Tencer AH, Zeng L, Lin K, Zhu L, Li Q, Lachance C, Ospina RR, Tong Q, Cheung KL, Yang S, Biswas S, Xuan H, Gatchalian J, Alamillo L, Wang J, Jang SM, Klein BJ, Lu Y, Ernst P, Strahl BD, Rothbart SB, Walsh MJ, Cleary ML, Côté J, Shi X, Zhou MM, Kutateladze TG. Structure-function relationship of ASH1L and histone H3K36 and H3K4 methylation. Nat Commun. 2025 Mar 06; 16(1):2235.
-
Jutabha P, Kumar V, Anzai N, Rice PJ, Lightner JW, Endou H, Wempe MF. Benzbromarone Analog SAR: Potent hURAT1 (SLC22A12) Inhibitors and Drug Transporter Interaction Studies. Drug Des Devel Ther. 2025; 19:1377-1392.
-
Garzan A, Ahmed SK, Haese NN, Sulgey G, Medica S, Smith JL, Zhang S, Ahmad F, Karyakarte S, Rasmussen L, DeFilippis V, Tekwani B, Bostwick R, Suto MJ, Hirsch AJ, Morrison TE, Heise MT, Augelli-Szafran CE, Streblow DN, Pathak AK, Moukha-Chafiq O. 4-Substituted-2-Thiazole Amides as Viral Replication Inhibitors of Alphaviruses. J Med Chem. 2024 Dec 12; 67(23):20858-20878.
-
Han X, Alameh MG, Xu Y, Palanki R, El-Mayta R, Dwivedi G, Swingle KL, Xu J, Gong N, Xue L, Shi Q, Yoon IC, Warzecha CC, Wilson JM, Weissman D, Mitchell MJ. Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution. Nat Biomed Eng. 2024 Nov; 8(11):1412-1424.
-
Harris SL, Dutta S, Liu N, Wollenberg T, Wang X. Extended structure-activity relationship studies of the [1,2,5]oxadiazolo[3,4-b]pyrazine-containing colistin adjuvants. Bioorg Med Chem Lett. 2025 Jan 01; 115:130008.
-
Stokes EG, Kim H, Ko J, Aoto J. A Systematic Structure-Function Characterization of a Human Mutation in Neurexin-3a Reveals an Extracellular Modulatory Sequence That Stabilizes Neuroligin-1 Binding to Enhance the Postsynaptic Properties of Excitatory Synapses. J Neurosci. 2024 Oct 09; 44(41).
-
Ren L, Moreno D, Baer BR, Barbour P, Bettendorf T, Bouhana K, Brown K, Brown SA, Fell JB, Hartley DP, Hicken EJ, Laird ER, Lee P, McCown J, Otten JN, Prigaro B, Wallace R, Kahn D. Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer. J Med Chem. 2024 08 08; 67(15):13019-13032.
-
Gardner L, Rossi J, Armstrong B, Muse M, LaVeck A, Blevins MA, Zhang L, Ford HL, Zhao R, Wang X. Rational Design of Novel Allosteric EYA2 Inhibitors as Potential Therapeutics for Multiple Brain Cancers. ChemMedChem. 2024 Sep 16; 19(18):e202400179.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|